Logo

Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma

Share this

Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma

Shots:

  • The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg- qd) as monothx in adults patients previously treated- LA or metastatic cholangiocarcinoma with documented FGF/FGFR status divided into 3 cohorts: Cohort A (N=107- FGFR2 fusions or rearrangements)- Cohort B (N=20- other FGF/FGFR genetic alterations) or Cohort C (N=18- no FGF/FGFR genetic alterations)  
  • P-II FIGHT-202 results: ORR 36%- mDOR 7.5 mos.- DCR 82%- mPFS 6.9mos.- Preliminary OS 21.1mos.- well-tolerated results; Presented at ESMO 2019  
  • Pemigatinib is a selective oral inhibitor of FGFR isoforms 1- 2 and 3- also received FDA’s Breakthrough Therapy Designation for the treatment of previously treated- advanced/metastatic or unresectable FGFR2 translocated cholangiocarcinoma with its planned NDA submission to the US FDA before end of H2’19

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions